# EDGAR Filing Document

**Accession Number:** 0001822791
**File Stem:** 0001104659-26-003464
**Filing Date:** 2026-1
**Character Count:** 10788
**Document Hash:** 84b835032c733c22d4dea0b92a8acdab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-003464.hdr.sgml**: 20260113

**ACCESSION NUMBER**: 0001104659-26-003464

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260109

**FILED AS OF DATE**: 20260113

**DATE AS OF CHANGE**: 20260113

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Mosca Alison
- **CENTRAL INDEX KEY:** 0001835537

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39834
- **FILM NUMBER:** 26531119

**MAIL ADDRESS:**
- **STREET 1:** 26 PATRIOT PLACE, SUITE 301
- **CITY:** FOXBORO
- **STATE:** MA
- **ZIP:** 02035
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Clene Inc.
- **CENTRAL INDEX KEY:** 0001822791
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 852828339
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 6550 SOUTH MILLROCK DRIVE, SUITE G50
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84121
- **BUSINESS PHONE:** 801-676-9695

**MAIL ADDRESS:**
- **STREET 1:** 6550 SOUTH MILLROCK DRIVE, SUITE G50
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chelsea Worldwide Inc.
- **DATE OF NAME CHANGE:** 20200827

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Mosca Alison<br><sub>(Last) (First) (Middle)</sub><br>6550 SOUTH MILLROCK DRIVE<br>SUITE G50<br><sub>(Street)</sub><br>SALT LAKE CITY, UT 84121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-01-09 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Clene Inc. [ CLNN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-01-09 |  | J<sup>(1)</sup> |  | 57219 | D | $0 | 263833 | I | By LLC<sup>(2)</sup> |
| Common Stock | 2026-01-13<sup>(3)</sup> |  | A |  | 16667 | A | 6.00<sup>(4)</sup> | 280500 | I | By LLC<sup>(2)</sup> |
| Common Stock |  |  |  |  |  |  |  | 1973 | D |  |
| Common Stock |  |  |  |  |  |  |  | 150333 | I | By LP<sup>(5)</sup> |
| Common Stock |  |  |  |  |  |  |  | 72997 | I | By Trust<sup>(6)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Tranche B Warrants (Right to buy) | $30.00 | 2026-01-09 |  | J<sup>(1)</sup> |  |  | 57219 | 2023-06-16 | <sup>(7)</sup> | Common Stock | 57219 | $0 | 62500 | I | By LLC<sup>(2)</sup> |
| Tranche A Warrants (Right to buy) | $22.00 | 2026-01-09 |  | J<sup>(1)</sup> |  |  | 57219 | 2023-06-16 | <sup>(8)</sup> | Common Stock | 57219 | $0 | 62500 | I | By LLC<sup>(2)</sup> |
| Series A Warrants (Right to buy) | 6.00<sup>(9)</sup> | 2026-01-13 |  | A |  | 20000<sup>(10)</sup> |  | 2026-01-09 | 2029-01-09 | Common Stock | <sup>(10)</sup> | <sup>(4)</sup> | 20000 | I | By LLC<sup>(2)</sup> |
| Series B Warrants (Right to buy) | 6.00<sup>(11)</sup> | 2026-01-13 |  | A |  | 46667<sup>(12)</sup> |  | 2026-01-09 | 2029-01-09 | Common Stock | <sup>(12)</sup> | <sup>(4)</sup> | 46667 | I | By LLC<sup>(2)</sup> |

---

### Footnotes:

(1) The transaction reported on this line represents a distribution in kind by the limited liability company to a limited partner for no consideration.

(2) The securities are owned by Kensington Clene 2021, LLC. Ms. Mosca is the sole manager of and owns a minority interest in Kensington Clene 2021, LLC. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

(3) Kensington Clene 2021, LLC entered into a Securities Purchase Agreement with Clene Inc. and the other parties thereto, dated January 8, 2026, for the purchase of 16,667 shares of the Company's common stock, Series A Warrants to purchase 20,000 shares of the Company's common Stock and Series B Warrants to purchase 46,667 shares of the Company's common stock, closing effective January 13, 2026.

(4) The price of each Unit is $6.50; one Unit consists of one share of Common Stock of Clene Inc., one Series A Warrant and one Series B Warrant.

(5) The securities are owned by the Kensington Investments, L.P. Ms. Mosca is the chief executive officer of Kensington Investments, L.P. The shares owned by the Kensington Investments, L.P. may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Investments, L.P., for which she does not have a pecuniary or profits interest.

(6) The securities are owned by the Robert C. Gay 1998 Family Trust. Ms. Mosca is the trustee of the Robert C. Gay 1998 Family Trust. The shares owned by the Robert C. Gay 1998 Family Trust may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca has no pecuniary or profits interest in the shares held by the Robert C. Gay 1998 Family Trust.

(7) The Tranche B Warrants will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the FDA approval of a New Drug Application from the Company. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

(8) The Tranche A Warrants will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the FDA accepts a New Drug Application from the Company. The shares owned by Kensington Clene 2021, LLC may be deemed to be beneficially owned by Ms. Mosca. Ms. Mosca disclaims all shares owned by Kensington Clene 2021, LLC for which she does not have a pecuniary or profits interest.

(9) The exercise price for each Series A Warrant will increase from $6.00 to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the U.S. Food and Drug Administration's (the "FDA") posted action date under the Prescription Drugs User Fee Act for the Company's new drug application ("NDA") for CNM-Au8 (the "Series A Trigger Announcement") or (b) the volume-weighted average price (the "VWAP") of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the Series A Trigger Announcement.

(10) The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $6,684,000 by the applicable exercise price.

(11) The exercise price for each Series B Warrant will increase from $6.00 to $12.50 per share if: (i) the Series B Warrant is exercised prior to the Company's public announcement of its receipt of written approval from the FDA of its NDA for CNM-Au8 in ALS or (ii) the VWAP of the Company's common stock is equal to or greater than $25.00 on the associated measurement date. The exercise price of the Series B Warrant will increase to $10.00 per share if the VWAP of the Company's common stock is equal to or greater than $20.00 on the associated measurement date.

(12) The reporting person will be entitled to purchase its pro rata share of the number of shares of common stock determined by dividing $15,596,000 by the applicable exercise price.

**Signature:** /s/ Alison Mosca  
**Date:** 2026-01-13

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**